Zynerba Pharmaceuticals Announces Adjournment of Annual Meeting
June 30 2021 - 7:00AM
Zynerba Pharmaceuticals, Inc. (Nasdaq: ZYNE), the leader in
innovative pharmaceutically-produced transdermal cannabinoid
therapies for rare and near-rare neuropsychiatric disorders, today
announced that it has adjourned its 2021 Annual Meeting of
Stockholders due to a lack of quorum. 49% of shares were voted,
just below the 50% required for a quorum. The adjourned meeting
will be reconvened at 9:00 AM EDT on Tuesday, August 3, 2021. The
reconvened annual meeting will also be a "virtual" meeting of
stockholders. The record date for the annual meeting continues to
be April 14, 2021. A stockholder may use one of the following
simple methods to vote:
- Vote by Internet at www.proxyvote.com until 11:59 PM EDT
on August 2, 2021 using the control number appearing on the proxy
card.
- Vote by telephone by calling the toll-free telephone number
1-800-776-9437 until 11:59 PM EDT on August 2, 2021 using their
control number appearing on the proxy card.
- Vote by mail by marking, dating and signing the proxy card, and
returning it in the postage-paid envelope provided to American
Stock Transfer, Inc.
- Vote at the virtual Annual Meeting by joining the meeting at
https://web.lumiagm.com/236626312 (password: zyne2021) using the
control number included on the proxy card.
Proxies previously submitted in respect of the annual meeting
will be voted at the reconvened annual meeting unless properly
revoked; stockholders who have previously submitted their proxy or
otherwise voted and who do not want to change their vote need not
take any action.
About Zynerba Pharmaceuticals, Inc. Zynerba
Pharmaceuticals is the leader in innovative
pharmaceutically-produced transdermal cannabinoid therapies for
rare and near-rare neuropsychiatric disorders. We are committed to
improving the lives of patients and their families living with
severe, chronic health conditions including Fragile X syndrome,
autism spectrum disorder, 22q11.2 deletion syndrome, and a
heterogeneous group of rare and ultra-rare epilepsies known as
developmental and epileptic encephalopathies. Learn more at
www.zynerba.com and follow us on Twitter at @ZynerbaPharma.
Cautionary Note on Forward-Looking
StatementsThis press release contains forward-looking
statements within the meaning of The Private Securities Litigation
Reform Act of 1995. We may, in some cases, use terms such as
“predicts,” “believes,” “potential,” “proposed,” “continue,”
“estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,”
“could,” “might,” “will,” “should” or other words that convey
uncertainty of future events or outcomes to identify these
forward-looking statements. Such statements are subject to numerous
important factors, risks and uncertainties that may cause actual
events or results to differ materially from the Company’s current
expectations. These and other risks are described in the Company’s
periodic reports, including the annual report on Form 10-K,
quarterly reports on Form 10-Q and current reports on Form 8-K,
filed with or furnished to the Securities and Exchange Commission
and available at www.sec.gov. Any forward-looking statements
that the Company makes in this press release speak only as of the
date of this press release. The Company assumes no obligation to
update forward-looking statements whether as a result of new
information, future events or otherwise, after the date of this
press release.
Zynerba Contacts
Peter VozzoWestwicke/ICROffice: 443.213.0505Cell:
443.377.4767Peter.Vozzo@Westwicke.com
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Aug 2024 to Sep 2024
Zynerba Pharmaceuticals (NASDAQ:ZYNE)
Historical Stock Chart
From Sep 2023 to Sep 2024